Navigation Links
Harvard Medical School Faculty Advances Drug Safety Research With IBM Business Analytics
Date:5/3/2011

ARMONK, N.Y., May 3, 2011 /PRNewswire/ -- IBM (NYSE: IBM) today announced that faculty from Harvard Medical School and Brigham & Women's Hospital will use IBM business analytics technology at the core of new research that examines the effectiveness of prescription drugs and spots potential safety issues.

(Logo: http://photos.prnewswire.com/prnh/20090416/IBMLOGO)

Harvard Medical research teams are conducting advanced pharmacoepidemiology studies that look at the effects of drugs in large numbers of people based on insurance claims data. Using an IBM Netezza data warehouse appliance, the research teams will expand its studies to analyze data from millions of de-identified patient records with the aim to develop new data-intensive drug safety research methods.

Pharmacoepidemiology research is designed to answer important questions such as which anti-inflammatory drugs carry a risk of heart attack, what osteoporosis medications are most often used with good results, or how cost-effective are some drugs in treating mental health disorders.

"We wanted a computing platform with massive analytics power, but was extremely simple to administer," said Dr. Sebastian Schneeweiss, Associate Professor of Medicine, Harvard Medical School and Vice Chief of the Brigham & Women's Hospital Division of Pharmacoepidemiology and Pharmacoeconomics. "As global healthcare evolves toward a learning healthcare system with a need for ongoing comparative effectiveness and safety research integrated in routine care, it is imperative that research methods evolve in parallel. IBM Netezza will accelerate our ability to devise, test and publish new computationally intensive algorithms applied to ever larger longitudinal healthcare databases that we hope will become the gold standard for researchers globally."

Dr. Schneeweiss is the principal investigator of the AHRQ-funded DEcIDE Methods Center and Co-Chair of the Methods Core of the FDA-funded Mini Sentinel project. The study of patterns of health and illness associated with prescription drugs over long periods of time help determine which treatments are proven to have the best outcomes, and which are most viable for specific populations of patients. IBM Netezza business analytics technology will help Dr. Schneeweiss' research team establish newer and more sophisticated analytic algorithms that can be automated to produce more accurate results.

"Our research lab is focused on the best ways to automate the continuous evaluation of the safety of medications, and we require fast systems to assemble and analyze data," said Dr. Jeremy Rassen, Assistant Professor of Medicine at Harvard Medical School. "IBM Netezza puts us ahead of the curve, including capabilities for parallelized in-database analytics. We have already seen orders of magnitude performance improvement, without the use of any database administrator time, and system maintenance is done by our researchers and analysts."

Another area of research for Harvard Medical will be health economics and outcomes research (HEOR). Once the effectiveness of medications is established, pharmaceutical companies and health insurers have teams of HEOR analysts to demonstrate the value of new medical products for pricing and coverage decisions to provide higher quality of care. Intelligently mining claims data with a powerful analytics platform like IBM Netezza is often the best and fastest way to answer questions about the most effective therapies.

"The ability to glean insight and act on the analysis of massive amounts of claims data will help Harvard Medical School extend its reputation as one of the largest and most respected medical research organizations in the world," said Arvind Krishna, general manager, IBM Information Management.

About IBM

For information about IBM Netezza, please visit: www.netezza.com.

For Information on IBM Information Management, please visit: http://www.ibm.com/software/data/information-on-demand/

IBM Netezza
Payal Patel Cudia
+1 (508) 382-8373
ppcudia@us.ibm.com


'/>"/>
SOURCE IBM
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Tone Deafness Explained, from the Harvard Health Letter
5. For Most, Good Oral Care Does More Than Antibiotics to Prevent Dental-Related Heart Problems, Reports the Harvard Heart Letter
6. Your Hearing May be at Risk, Says Harvard Mens Health Watch
7. Testosterone May Improve Mental Function, From the Harvard Mens Health Watch
8. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
9. BASF Officially Launches the Collaborative Advanced Research Initiative at Harvard University
10. Harvard Study Shows Folic Acid, B Vitamins in Animi-3(R) May Prevent Vision Loss
11. Edifecs, CAQH and Harvard Pilgrim Health Care Will Examine CORE Phase II Testing Outcomes and Lessons Learned at HIMSS09 Interoperability Showcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... environments  Oticon , industry leaders in ... the launch of Oticon Opn ™, the world,s ... world of possibilities for IoT devices.      ... Opn, Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... ... ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect Plugin ... whole new perspective by using the title layers in ProSlice Levels to split-up ... Levels contains over 30 Different presets to choose from. FCPX users can ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
Breaking Medicine News(10 mins):